BIORCHESTRA Co., Ltd. Mediaroom

BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program

* Recognition of outstanding in-vivo outcomes from a lead RNA program in CNS * Underpinned by pr...

2023-07-17 21:28 2051

BIORCHESTRA Invited to Present Update on Central Nervous System Lead Program (BMD-001) and IV-Formulated siRNA Data at BIO2023 International Conference

* Presentation:"Successfully Achieving Intravenous (IV)-formulated RNA Delivery to the Brain, Evi...

2023-06-01 20:00 2245

BIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins the Republic of Korea (ROK) Official State Visit to the United States

* The Official State visit by the President of the Republic of Korea marks the 70th anniversary o...

2023-04-25 20:00 1523

BIORCHESTRA Announces Significant Progress in Studies of BMD-001 Drug Program

* Encouraging non-human primate (NHP) findings support the progression of IV-formulatedBMD-001 ah...

2023-04-24 20:00 1416

BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer

CAMBRIDGE, Mass. and DAEJEON, South Korea, April 5, 2023 /PRNewswire/ -- BIORCHESTRA

2023-04-05 20:00 2376

BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer

BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies

Exclusive Research and Option Agreement With Global Biopharmaceutical Company to Leverage BIORCHEST...

2023-03-27 20:00 1413

BIORCHESTRA Participating in Two Upcoming Therapeutic RNA-Focused Events

CAMBRIDGE, Mass. and DAEJEON, South Korea, March 8, 2023 /PRNewswire/ -- BIORCHESTRA

2023-03-08 22:47 1893

BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy

* A leader in creating jobs through the advancement of RNA-based therapeutics * A contributor to...

2022-12-15 21:00 1517

BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy

BIORCHESTRA announces that BMD-001 reduces Amyloid-β and Tau in non-human primate animal model of Alzheimer's Disease at the RNA Leaders USA Conference in Boston

BOSTON, Nov. 8, 2022 /PRNewswire/ -- Dr. Branden Ryu, CEO and Founder of BIORCHESTRA Ltd. (S. Korea...

2022-11-08 15:59 1728

BIORCHESTRA announces that BMD-001 reduces Amyloid-β and Tau in non-human primate animal model of Alzheimer's Disease at the RNA Leaders USA Conference in Boston

BOSTON, Nov. 8, 2022 /PRNewswire/ -- Dr. Branden Ryu, CEO and Founder of BIORCHESTRA Ltd. (S. Korea...

2022-11-08 15:30 1787

BIORCHESTRA announces that BMD-001 reduces Amyloid-β and Tau in non-human primate animal model of Alzheimer's Disease at the RNA Leaders USA Conference in Boston

BIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology

BOSTON, Mass., Aug. 23, 2022 /PRNewswire/ -- BIORCHESTRA, headquartered in Daejeon,South Korea, app...

2022-08-23 20:00 2087

BIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology

BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer's disease and drug delivery system technology at the 2022 BIO International Convention

BOSTON, June 9, 2022 /PRNewswire/ -- BIORCHESTRA Co., Ltd (BIORCHESTRA), is scheduled to give a com...

2022-06-09 20:30 2110

BIORCHESTRA Participated in Formulation and Delivery

BOSTON, May 12, 2022 /PRNewswire/ -- BIORCHESTRA is a leading RNA therapeutics company that develop...

2022-05-12 21:00 1795

BIORCHESTRA Participated in Formulation and Delivery

BIORCHESTRA Announces 45 Million USD Series C Fundraising

SEOUL, South Korea, Feb. 22, 2022 /PRNewswire/ -- BIORCHESTRA is a leading RNA therapeutics company...

2022-02-23 11:26 1654

BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics

SEOUL, South Korea, Jan. 4, 2022 /PRNewswire/ -- BIORCHESTRA and SK Biopharmaceuticals announcedtod...

2022-01-05 08:07 1919

BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics

BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston

BOSTON, Nov. 5, 2021 /PRNewswire/ -- South Korean bio-venture BIORCHESTRA Co. Ltd., is an RNA thera...

2021-11-08 22:59 2766

BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO "Dr. Louis St. L. O'Dea" as CMO of BIORCHESTRA

BOSTON, Sept. 23, 2021 /PRNewswire/ -- BIORCHESTRA is a bio-tech company focused on the identifica...

2021-09-23 20:00 2335

Latest News